Form 4: Alkermes COO's Routine Stock Transactions

Alkermes' Chief Operating Officer, Blair C. Jackson, acquired shares through RSU vesting and sold a portion for tax obligations.

Summary

• Blair Curtis Jackson, Executive Vice President and Chief Operating Officer of Alkermes plc, reported changes in beneficial ownership.
• On February 26, 2026, Jackson acquired 8,322 ordinary shares upon the vesting of a Restricted Stock Unit (RSU) award.
• Each RSU represents a contingent right to receive one ordinary share.
• The RSU award vests in four equal annual installments, with the first installment commencing on February 26, 2025.
• Concurrently, Jackson disposed of 3,695 ordinary shares at a price of $30.73 per share to cover tax liabilities related to the RSU vesting.
• Following these transactions, Jackson directly beneficially owns 241,308 ordinary shares.
• Jackson also holds 16,645 Restricted Stock Units as derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of RSUs is a positive for the executive and reflects ongoing compensation, while the sell-to-cover is a routine, non-discretionary transaction.

Positives

• The vesting of 8,322 Restricted Stock Units indicates the payout of long-term incentive compensation to a key executive, aligning management interests with shareholder value.
• The executive's continued direct beneficial ownership of 241,308 ordinary shares demonstrates a significant stake in the company.

Negatives

• The disposal of 3,695 ordinary shares for tax withholding, while a routine 'sell-to-cover' transaction, reduces the executive's direct shareholding by that amount.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and sell-to-cover, are common across the pharmaceutical and biotechnology industries. These transactions reflect standard executive compensation practices and are generally not indicative of significant shifts in company fundamentals or strategic direction, unlike large open-market purchases or sales.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice in the pharmaceutical and biotechnology sectors, aligning with global benchmarks for long-term incentive plans.
• The 'sell-to-cover' mechanism for tax obligations upon RSU vesting is a standard and efficient method for executives to manage tax liabilities, consistent with practices observed at comparable companies such as Pfizer, Johnson & Johnson, and Merck.

Stakeholder Impact

• Shareholders: The transaction represents a routine change in insider ownership, with a slight increase in the executive's direct shareholding after tax withholding, which generally aligns executive interests with shareholder value.
• Employees: The RSU vesting demonstrates the company's commitment to long-term incentive compensation for its executives, which can positively influence employee morale and retention strategies.

Next Steps

• The remaining 16,645 Restricted Stock Units will continue to vest in future annual installments as per the original award schedule.

Key Dates

Keywords

Alkermes plc, ALKS, Blair Curtis Jackson, EVP Chief Operating Officer, Restricted Stock Units, RSU vesting, insider transaction, Form 4, beneficial ownership, equity compensation, sell-to-cover